Miranda Claudia, Mazzoni Mara, Sensi Marialuisa, Pierotti Marco A, Greco Angela
Molecular Mechanisms Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Genes Chromosomes Cancer. 2014 Oct;53(10):875-80. doi: 10.1002/gcc.22200. Epub 2014 Jun 26.
Cutaneous melanoma is the most aggressive form of skin cancer, with a complex and heterogeneous aetiology. Deregulation of the mitogen activated protein kinase cascade is common in melanoma, due to activating mutations in the BRAF and NRAS genes. Genetic studies and high-throughput screening technologies have recently identified several somatic mutations affecting different receptor tyrosine kinase (RTK) genes. For the majority of these, however, the contribution to the complexity of melanoma biology has not been assessed. Among these, two novel missense somatic mutations (M379I and R577G) have recently been identified in the gene encoding the neurotrophic RTK NTRK1. The NTRK1 melanoma-associated point mutations were introduced in a NTRK1 expression plasmid. Functional characterization of mutants was assessed after transient and stable transfection in HeLa and NIH3T3 cells, respectively. We showed that M379I and R577G NTRK1 receptors do not display the kinase as constitutively activated and are functionally indistinguishable from the wild-type NTRK1 receptor. Our results indicate that a causative role for M379I and R577G NTRK1 mutations in melanoma development is highly unlikely. This supports the issue that, in parallel to systematic large scale cancer genome screening, functional studies are required to distinguish between mutations that play a causative role in tumor development and others that may only be passenger changes.
皮肤黑色素瘤是最具侵袭性的皮肤癌形式,其病因复杂且具有异质性。由于BRAF和NRAS基因的激活突变,丝裂原活化蛋白激酶级联反应失调在黑色素瘤中很常见。遗传研究和高通量筛选技术最近发现了几种影响不同受体酪氨酸激酶(RTK)基因的体细胞突变。然而,对于其中大多数突变,尚未评估其对黑色素瘤生物学复杂性的影响。其中,最近在编码神经营养性RTK NTRK1的基因中发现了两种新的错义体细胞突变(M379I和R577G)。将NTRK1黑色素瘤相关点突变引入NTRK1表达质粒中。分别在HeLa和NIH3T3细胞中进行瞬时和稳定转染后,评估突变体的功能特性。我们发现M379I和R577G NTRK1受体不会表现出激酶组成性激活,并且在功能上与野生型NTRK1受体没有区别。我们的结果表明,M379I和R577G NTRK1突变在黑色素瘤发展中起致病作用的可能性极小。这支持了这样一个观点,即与系统性大规模癌症基因组筛查并行,需要进行功能研究以区分在肿瘤发展中起致病作用的突变和其他可能只是过客变化的突变。